Re: Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients with Advanced Urothelial Bladder Cancer

Sam S. Chang

首页> 外文期刊>The Journal of Urology >Re: Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients with Advanced Urothelial Bladder Cancer

【24h】

Re: Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients with Advanced Urothelial Bladder Cancer

机译：Re：Durvalumab（Medi4736）的安全性和有效性，患有先进的尿路上皮膀胱癌患者的反编程细胞死亡配体-1免疫检查点抑制剂

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The Journal of Urology》 |2018年第2期|共2页
作者
Sam S. Chang;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类泌尿科学（泌尿生殖系疾病）;
关键词

相似文献

外文文献
中文文献
专利

1. Re: Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients with Advanced Urothelial Bladder Cancer [J] . Sam S. Chang The Journal of Urology . 2018,第2期

机译：Re：Durvalumab（Medi4736）的安全性和有效性，患有先进的尿路上皮膀胱癌患者的反编程细胞死亡配体-1免疫检查点抑制剂
2. Efficacy and safety of programmed cell death-1/programmed cell death ligand-1 inhibitors in advanced urothelial malignancy: A systematic review and meta-analysis [J] . Smita Pattanaik, Sumit Dey, Nishant Jaiswal, Indian Journal of Urology: IJU: Journal of the Urological Society of India . 2019,第2期

机译：程序性细胞死亡-1 /程序性细胞死亡配体-1抑制剂在晚期尿路上皮恶性肿瘤中的疗效和安全性：系统评价和荟萃分析
3. Efficacy and safety of a modified whole tumor cell targeted immunotherapy in patients with advanced breast cancer alone and in combination with immune checkpoint inhibitors [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：一种改性全肿瘤细胞靶向免疫疗法的疗效和安全性，单独服用晚期乳腺癌患者，与免疫检查点抑制剂组合
4. 4-aminobiphenyl DNA adducts of urothelial cells from smokers as biomarkers of bladder cancer risk: optimization of sample preparation and nanoLC-ESI-MS/MS. [C] . Joshua J Klaene, Samantha J Sokup, Kaila Norton, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2012

机译：4-氨基双苯基DNA加入吸烟者作为膀胱癌风险的生物标志物的尿液细胞：样品制备和Nanolc-ESI-MS / MS的优化。
5. Immune-Related Adverse Events in Cancer Patients Being Treated with Immune Checkpoint Inhibitors [D] . Byrne, Margaret M. 2021

机译：用免疫检查点抑制剂治疗癌症患者免疫相关不良事件
6. Safety and Efficacy of Durvalumab (MEDI4736) an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor in Patients With Advanced Urothelial Bladder Cancer [O] . Christophe Massard, Michael S. Gordon, Sunil Sharma, -1

机译：一种抗编程性细胞死亡配体1免疫检查点抑制剂Durvalumab（MEDI4736）在晚期尿路上皮癌患者中的安全性和有效性
7. 57O Efficacy, safety and tolerability of MEDI4736 (durvalumab D), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC [O] . D.L. Gibbons, L.Q. Chow, D.-W. Kim, 2016

机译：57O疗效，安全性和耐受性和MEDI4736（Durvalumab D），一种人IgG1抗程序化细胞死亡 - 1（PD-L1）抗体，与Gefitinib（g）联合：Tki-Naïve患者中的I相扩张（PTS）与EGFR突变体NSCLC

Re: Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients with Advanced Urothelial Bladder Cancer

著录项

相似文献

相关主题

期刊订阅